Anal canal carcinoma in situ

Summary

Anal canal carcinoma in situ (MONDO:0004707) is a cancer and 1 clinical trial. A subtype of rectum carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anal canal carcinoma in situ
Mondo ID	MONDO:0004707
DOID	DOID:9087
ICD-11	1447034
NCIT	C7794
SNOMED CT	92531006
UMLS	C2242854
MedGen	412201
GARD	0024093
Anatomy (UBERON)	UBERON:0000159
Is cancer (heuristic)	yes

Also known as: anal canal in situ carcinoma · carcinoma in situ of anal canal · stage 0 anal canal cancer · stage 0 anal canal cancer aJCC v6 · stage 0 anal canal cancer aJCC v6 and v7 · stage 0 anal canal cancer aJCC v7 · stage 0 anal canal carcinoma · stage 0 anal canal carcinoma aJCC v6 and v7 · stage 0 anal carcinoma aJCC v6 and v7 · stage 0 anal carcinoma in situ

Disease family

This is a subtype of rectum carcinoma in situ. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › intestine carcinoma in situ › rectum carcinoma in situ › anal canal carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02437851	PHASE2	COMPLETED	Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection